Pharmacological treatments of COVID-19
Abstract The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
---|---|
Enthalten in: |
Pharmacological reports - 72(2020), 6 vom: 20. Aug., Seite 1446-1478 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sahebnasagh, Adeleh [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Anmerkungen: |
© Maj Institute of Pharmacology Polish Academy of Sciences 2020 |
---|
doi: |
10.1007/s43440-020-00152-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2121615253 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2121615253 | ||
003 | DE-627 | ||
005 | 20230504185128.0 | ||
007 | tu | ||
008 | 230504s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s43440-020-00152-9 |2 doi | |
035 | |a (DE-627)OLC2121615253 | ||
035 | |a (DE-He213)s43440-020-00152-9-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 15,3 |2 ssgn | ||
084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
100 | 1 | |a Sahebnasagh, Adeleh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacological treatments of COVID-19 |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Maj Institute of Pharmacology Polish Academy of Sciences 2020 | ||
520 | |a Abstract The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a Pharmacology | |
650 | 4 | |a Pneumonia | |
650 | 4 | |a SARS-CoV2 | |
700 | 1 | |a Avan, Razieh |4 aut | |
700 | 1 | |a Saghafi, Fatemeh |4 aut | |
700 | 1 | |a Mojtahedzadeh, Mojataba |4 aut | |
700 | 1 | |a Sadremomtaz, Afsaneh |4 aut | |
700 | 1 | |a Arasteh, Omid |4 aut | |
700 | 1 | |a Tanzifi, Asal |4 aut | |
700 | 1 | |a Faramarzi, Fatemeh |4 aut | |
700 | 1 | |a Negarandeh, Reza |4 aut | |
700 | 1 | |a Safdari, Mohammadreza |4 aut | |
700 | 1 | |a Khataminia, Masoud |4 aut | |
700 | 1 | |a Rezai Ghaleno, Hassan |4 aut | |
700 | 1 | |a Habtemariam, Solomon |4 aut | |
700 | 1 | |a Khoshi, Amirhosein |0 (orcid)0000-0001-9520-1857 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Springer International Publishing, 2005 |g 72(2020), 6 vom: 20. Aug., Seite 1446-1478 |w (DE-627)485244918 |w (DE-600)2186248-5 |w (DE-576)435514369 |x 1734-1140 |7 nnns |
773 | 1 | 8 | |g volume:72 |g year:2020 |g number:6 |g day:20 |g month:08 |g pages:1446-1478 |
856 | 4 | 1 | |u https://doi.org/10.1007/s43440-020-00152-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
951 | |a AR | ||
952 | |d 72 |j 2020 |e 6 |b 20 |c 08 |h 1446-1478 |